Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
BeiGene Australia Pty Ltd
Other Non-Commercial Sponsor
Lymphoma Study Association
Patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after receiving either an autologous hematopoietic stem cell transplantation (HSCT) or at least 2 prior systemic chemotherapy regimens and are not candidates for autologous or allogeneic HSCT, will receive 200 mg intravenously (IV) every 3 weeks (Q3W)